Victoria General Hospital
Halifax, Nova Scotia, B3H1V7, Canada
Location status: Recruiting
Location contact
Beverly Lieuwen
CONTACT
Michael J Kucharczyk, MB BCh BAO MPH FRCPC
CONTACT
NCT Number: NCT05024162
Prostate cancer is the most common cancer diagnosed in men in Canada. Magnetic resonance imaging (MRI) may become a valuable tool to non-invasively identify prostate cancer and assess its biological aggressiveness, which in turn will help doctors make better decisions about how to treat an individual patient's prostate cancer.
Despite the promise of MRI for detecting and characterizing prostate cancer, there are several recognized limitations and challenges. These include lack of standardized interpretation and reporting of prostate MRI exams.
The investigators propose to validate and improve a computer program computerized prediction tool that will use information from MR images to inform us how aggressive a prostate cancer is. The hypothesis is that this computer-aided approach will increase the reproducibility and accuracy of MRI in predicting the tumor biology information about the imaged prostate cancer.
Interested in participating?
Request InfoMale
Interventional
Not applicable
Halifax, Nova Scotia, B3H1V7, Canada
Location status: Recruiting
Beverly Lieuwen
CONTACT
Michael J Kucharczyk, MB BCh BAO MPH FRCPC
CONTACT
Prostate biopsies are the gold standard assessment of how prostate cancer is diagnosed and how low risk prostate cancers are surveilled. The investigators have produced a machine-learning based algorithm which uses MRI characteristics (radiomic features or textures) to predict the results of a prostate biopsy. The field has numerous concerns that such radiomic based predictions will not be reproducible, as there as so many subtle changes between MRI scans of different patients.
The interventions are the use of the MRT and the use of a second MRI of the prostate (MRI-P).
Two primary outcomes will be investigated. First, the existing radiomics predictive model, labeled as the MRI-P based Radiomics Tool (MRT) will predict the Grade Group (GG) and compare it to the gold standard, pathologist's evaluation of the Grade Group (GG). Second, the stability of the predicted GG between two shortly spaced MRI-Ps will be compared.
Patients with a detectable prostate nodule on MRI-P which localizes to a biopsy confirmed prostate cancer will be approached for enrollment. If enrolled, participants will attend for a subsequent MRI-P in a brief time frame relative to the acquisition of the first MRI-P. Attempts will be made to obtain participants that allow for even distribution among all GGs.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
An appropriate diagnostic MRI-P, defined as:
An appropriate diagnostic biopsy, defined as:
Exclusion criteria
Predicted Grade Group (GG) by the MRI-based Radiomics Tool (MRT) at each Magnetic Resonance Imaging of the Prostate (MRI-P)
MRT's predicted GG at second MRI-P.
Time frame: Baseline, 8 weeks
Stability of participants' MRT classification (each of the five GG groups) between two shortly spaced MRIs.
Time frame: Baseline
The accuracy of the GG classification from the MRT. Will be compared to the Gold Standard - prostate biopsy results. The percentage of MRT classifications that show agreement between the two methods (i.e. Gold Standard and MRT) in terms of GG classification will be reported.
Time frame: 8 weeks
The accuracy of the GG classification from the MRT. Will be compared to the Gold Standard - prostate biopsy results. The percentage of MRT classifications that show agreement between the two methods (i.e. Gold Standard and MRT) in terms of GG classification will be reported.
Time frame: At study completion, 2 years.
Gwet's first order agreement coefficient; McNemar's test to test agreement across the two time points, regarding GG classification agreement.
Intra-class correlation coefficient (ICC) will to test the reliability of individual radiomic features at time points 1 and 2. Stability will be defined as an ICC ≥0.85.
Ordinal logistic regression with a cumulative logic link will be used to model GG classification. Clinical covariates, PIRADS scores, and exclusively "reliable" radiomic features will be explored in secondary analyses.
Contact information is provided by the study sponsor or research team.
Beverly A Lieuwen, BSc
CONTACT
Dr. Michael Kucharczyk
CONTACT
Nova Scotia Health Authority
Other
Can Magnetic Resonance Imaging of the Prostate Combined With a Radiomics Evaluation Determine the Invasive Capacity of a Tumour (Can MRI-PREDICT)
Acronym: MRI-PREDICT
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06625970
Genital Diseases, Genital Diseases, Male
Brest, France
View Trial DetailsNCT06954337
Breast Cancer, Breast Diseases
Basking Ridge, New Jersey, United States
View Trial DetailsNCT02960022
Genital Diseases, Genital Diseases, Male
Anchorage, Alaska, United States
View Trial DetailsNCT07005154
Genital Diseases, Genital Diseases, Male
Huntsville, Alabama, United States
View Trial Details